Journal
CURRENT MEDICINAL CHEMISTRY
Volume 18, Issue 23, Pages 3576-3589Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986711796642517
Keywords
5 alpha-Reductase; 5 alpha-reductase inhibitors; benign prostatic hyperplasia; dihydrotestosterone; steroid; finasteride; azasteroid; 3-carboxylic acid; pregnane derivatives; natural products
Ask authors/readers for more resources
Benign prostatic hyperplasia (BPH) is a kind of common noncancerous prostate gland enlargement with growing tendency in recent years. 5 alpha-reductase is the key enzyme responsible for dihydrotestosterone biosynthesis and has been considered as an important target for designing inhibitors as potent therapeutic agents for BPH. Finasteride, the first steroidal 5 alpha-reductase inhibitor, has been marketed worldwide as a drug for BPH. During these years, many other novel types of 5 alpha-reductase inhibitors are being studied. This review summarizes recent advancement in steroidal 5 alpha-reductase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available